Young Youn Cho

Young Youn Cho

Auto-generated profile, based on publicly available information

Young Youn Cho

Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2017 in Hepatology
Verified
Journal Article
Closed access
MLMinjong Lee
Minjong Lee
GCGoh Eun Chung
Goh Eun Chung
JLJeong-Hoon Lee
Jeong-Hoon Lee
SOSohee Oh
Sohee Oh
JNJoon Yeul Nam
Joon Yeul Nam
JYJung-Hwan Yoon
Jung-Hwan Yoon

1 October 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
MLMinjong Lee
Minjong Lee
JLJeong-Hoon Lee
Jeong-Hoon Lee
SOSohee Oh
Sohee Oh
YJYoonhyuk Jang
Yoonhyuk Jang
WLWonik Lee
Wonik Lee
HLHyo‐Suk Lee
Hyo‐Suk Lee

5 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YCYoung Youn Cho
Young Youn Cho
MLMinjong Lee
Minjong Lee
HKHyo-Cheol Kim
Hyo-Cheol Kim
JCJin Wook Chung
Jin Wook Chung
YKYun Hwan Kim
Yun Hwan Kim
YKYoon Jun Kim
Yoon Jun Kim
Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib. We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics. At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01). HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.

25 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YCYuri Cho
Yuri Cho
DLDong Hyeon Lee
Dong Hyeon Lee
YLYun Bin Lee
Yun Bin Lee
MLMinjong Lee
Minjong Lee
JYJeong-Ju Yoo
Jeong-Ju Yoo
YKYoon Jun Kim
Yoon Jun Kim
The utility of fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) in initial staging of hepatocellular carcinoma (HCC) has yet to be fully explored. We assessed the usefulness of 18F-FDG PET/CT in initial staging of HCC. A total of 457 consecutive patients initially diagnosed with HCC at Seoul National University Hospital between 2006 and 2012 were evaluated retrospectively to assess the impact of 18F-FDG PET/CT on staging and compliancy with Milan criteria, relative to dynamic CT of liver and chest x-ray. Seven among the 457 patients studied showed a shift in Barcelona Clinic Liver Cancer [BCLC] stage (A→C: 6 patients; B→C: 1 patient) and 5 patients who had originally met Milan criteria no longer qualified. 18F-FDG PET/CT had value in initial staging of early (stage A) or intermediate (stage B) HCC, as determined by dynamic CT of liver and BCLC or AJCC classifications, whereas BCLC stage 0 and stage C tumors were unchanged (P<0.001). 18F-FDG PET/CT disclosed additional metastases in patients with American Joint Committee on Cancer [AJCC] T2 (2.7%), T3a (5.3%), and T3b (4.8%) classifications. In initial staging of HCC, 18F-FDG PET/CT provided additional information, impacting the patients with BCLC (stages A and B) and AJCC (T2 and T3) classifications. Its use might be thus appropriate for these patient subsets, especially if hepatic resection or liver transplantation is planned.

Verified
Journal Article
Open access
PDF file
JYJeong-Ju Yoo
Jeong-Ju Yoo
SYSu Jong Yu
Su Jong Yu
JNJuri Na
Juri Na
KKKyungmin Kim
Kyungmin Kim
YCYoung Youn Cho
Young Youn Cho
JYJung-Hwan Yoon
Jung-Hwan Yoon
This study aimed to examine whether inhibition of hexokinase (HK)-II activity enhances the efficacy of sorafenib in in-vivo models of hepatocellular carcinoma (HCC), and to evaluate the prognostic implication of HK-II expression in patients with HCC. We used 3-bromopyruvate (3-BP), a HK-II inhibitor to target HK-II. The human HCC cell line was tested as both subcutaneous and orthotopic tumor xenograft models in BALB/c nu/nu mice. The prognostic role of HK-II was evaluated in data from HCC patients in The Cancer Genome Atlas (TCGA) database and validated in patients treated with sorafenib. Quantitative real-time PCR, western blot analysis, and immunohistochemical staining revealed that HK-II expression is upregulated in the presence of sorafenib. Further analysis of the endoplasmic reticulum-stress network model in two different murine HCC models showed that the introduction of additional stress by 3-BP treatment synergistically increased the in vivo/vitro efficacy of sorafenib. We found that HCC patients with increased HK-II expression in the TCGA database showed poor overall survival, and also confirmed similar results for TCGA database HCC patients who had undergone sorafenib treatment. These results suggest that HK-II is a promising therapeutic target to enhance the efficacy of sorafenib and that HK-II expression might be a prognostic factor in HCC.

1 November 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
YLYun Bin Lee
Yun Bin Lee
JLJeong-Hoon Lee
Jeong-Hoon Lee
DLDong Hyeon Lee
Dong Hyeon Lee
HCHyeki Cho
Hyeki Cho
HAHongkeun Ahn
Hongkeun Ahn
HLHyo-Suk Lee
Hyo-Suk Lee
The emergence of multidrug-resistant (MDR) strains of hepatitis B virus (HBV) is a major concern. This study aimed to investigate the efficacy and safety of combination therapy with entecavir (ETV) plus tenofovir disoproxil fumarate (TDF) against MDR HBV. To adjust for differences in baseline characteristics, inverse probability weighting (IPW) using propensity scores for the entire cohort and weighted Cox proportional hazards models were applied. Ninety-three consecutive patients who were treated with ETV-TDF combination therapy for >6 months were included; at baseline, 45 were infected with HBV strains with genotypic resistance to lamivudine (LAM) and ETV (the LAM/ETV-R group), 28 with strains resistant to LAM and adefovir (ADV) (the LAM/ADV-R group), and 20 with strains resistant to LAM, ETV, and ADV (the LAM/ETV/ADV-R group). The median duration of rescue therapy was 13.0 (range, 6.7 to 31.7) months. Seventy-four of 93 patients (79.6%) achieved complete virologic suppression, after a median of 4.5 (95% confidence interval, 3.0 to 6.0) months. The cumulative probability of complete virologic suppression at month 6 was 63.6% (55.7%, 75.0%, and 65.0% in the LAM/ETV-R, LAM/ADV-R, and LAM/ETV/ADV-R groups, respectively). During the treatment period, these probabilities were not significantly different across the resistance profiles before and after IPW (P= 0.072 andP= 0.510, respectively). In multivariate analysis, a lower baseline HBV DNA level, but not resistance profiles, was an independent predictor of complete virologic suppression. Renal dysfunction was not observed during the treatment period. In conclusion, rescue therapy with ETV-TDF combination is efficient and safe in patients infected with MDR HBV strains regardless of the antiviral drug resistance profiles.